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Summary 
Antibodies directed against antigens present on renal  epithelial cells can cause membranous 
glomerulonephritis in experimental animals, which closely resembles the human form of this 
disease. However, most antibodies produced so far fail to cause the persistent and severe proteinuria 
that is seen in humans. In our search for new antibodies of this kind, we have now produced 
a monoclonal antibody (mAb) against mouse aminopeptidase A, a hydrolase that is present in 
the mouse kidney.  The mAb (ASD-4)  was prepared by fusion of mouse myeloma cells with 
splenocytes of Lou rats immunized with brush border (BB) membranes from mouse kidneys. 
ASD-4 is of the IgG1 subclass and reacts with a 140-kD protein as demonstrated by immuno- 
precipitation on radiolabeled  BB membranes. In indirect immunofluorescence and immuno- 
electronmicroscopy of normal mouse kidneys, ASD-4 was diffusely present on the BB of the 
$1 and $2 segments of the proximal tubules, and on the ceU membranes of the glomerular visceral 
epithelia. It also bound to cell membranes of nonglomerular endothelia, smooth muscle cells 
of arteries, and juxtaglomerular cells. After injection of ASD-4 into normal mice, an immediate 
homogeneous binding to the capillary wall was seen that gradually changed into a fine granular 
pattern after  1 d. This glomerular binding was followed by binding to the BB and basolateral 
membranes of the convoluted proximal tubules. Immediately after injection of ASD-4, a dose- 
dependent albuminuria occurred that lasted for at least  16 d. ASD-4 is thus a new rat mAb 
against a well-defined renal epithelial antigen that causes not only membranous glomerulonephritis 
after  a single injection in the mouse, but also severe albuminuria. 
O 
ne of the mechanisms that can result in immune com- 
plex formation in the glomerular capillary wall and even- 
tually can lead to functional and morphologic glomerular 
damage is the interaction of antibodies with intrinsic antigens 
on the glomerular visceral epithelial or endothelial cells (1-3). 
The most extensively studied example of such a mechanism 
is the Heymann nephritis in the rat, an experimental model 
of membranous glomerulonephritis, in which the glomer- 
ular damage and ensuing proteinuria is initiated by the binding 
of antibodies to a structural protein with a molecular mass 
of 330 kD located at discrete  sites on the cell membranes 
of the glomerular visceral epithelial cells (4-6). These findings 
from the Heymann nephritis in the rat have stimulated many 
investigators to characterize other cell membrane-bound an- 
tigens that might play a role in the formation of immune 
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complexes in the glomerulus and the induction of glomer- 
ular lesions and proteinuria. 
The hydrolase dipeptidyl peptidase IV (DPP IV) t is one 
of these antigens that has been reported to be involved in 
the induction of an immune complex glomerulonephritis 
(7-13). Injection of monoclonal or polyclonal antisera against 
DPP IV into rats or mice results in an immediate, transient 
glomerular binding, but induces only a mild proteinuria of 
short duration (7, 9, 11). An autologous phase with the for- 
mation of small subepithelial immune deposits develops after 
injection of polyclonal, but not of monoclonal anti-DPP IV 
antibodies.  However, in this phase there is no enhanced glo- 
merular permeability (11). In recent years, several other cell 
t Abbreviations used in  this paper: APA,  aminopeptidase  A;  APN, 
aminopeptidase N; BB, brush border; DPP IV, dipeptidyl peptidase IV; 
GBM,  glomerular  basement  membrane;  IEM,  immuno-electron 
microscopy; IF, immunofluorescence;  IP, immunoprecipitation; LM, light 
microscopy;  S4B, Sepharose 413. 
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of rats and rabbits (14-23),  but mAbs against only two of 
these can cause a glomerulonephritis accompanied by some 
degree of proteinuria in rats (17, 21). 
Until now, there are no data on we11-characterized glo- 
meruhr cell membrane-bound proteins that might be involved 
in an immune complex glomerulonephritis with massive al- 
buminuria in mice.  In this study, we described  a rat mAb 
against mouse aminopeptidase A  (APA), a hydrolase that, 
like DPP IV, is prominently present on the call membranes 
of glomerular visceral epithdial calls and brush border (BB) 
of proximal tubules. It is the first  mAb that can induce a 
severe albuminuria in mice after a single intravenous injection. 
Materials and Methods 
Materials.  Aquamount was purchased from BDH Chemicals 
Ltd., Poole, UK; Sephadex G-25, Sepharose 4B-coupled protein 
A, Sepharose 4B, and DEAE-Sephacel from Pharmacia, Uppsala, 
Sweden; paraplast from Amstelstad,  Amsterdam, The Netherlands; 
96-wen tissue  culture clusters  from Costar, Cambridge, MA; Hepes- 
buffered RPMI 1640 from M. A. Bioproducts,  Bethesda, MA; FCS 
from Gibco Laboratories,  Grand Island, NY; AP-15 filter from Mil- 
lipore Continental Water Systems,  Bedford, MA; isotyping kit for 
rat mAbs from Serotec, Oxford, UK; aprotinine (Trasylol) from 
Bayer, Leverkusen,  Germany; t-glutamic acid-c~-7-amido-4-methyl- 
coumarin  (Glu.AMC)  and  glycyl-L-proline-7-amino-4-methyl- 
coumarin-HBr (Gly.Prol.AMC) from Bachem, Bubendorf, Swit- 
zerland; t-alanine-7-amido-4-methyl-coumarin (Ala.AMC) from 
Serva GMBH and Co., Heidelberg, Germany; protein A-agarose 
from Sigma Chemical Co., St. Louis, MO; FITC-labeled rabbit 
anti-rat IgG from Cappel-Organon Technika NV, Turnhout, Bd- 
gium; FITC-labeled goat anti-mouse C3 from Nordic, Tilburg, 
The Netherlands; FITC-labded sheep anti-mouse IgG (heavy and 
light chains), F(ab')z fragment from Sigma Chemical Co.; perox- 
idase-labeled sheep anti-rat IgG, Fab fragment, from Sanbio, Uden, 
The Netherlands; Iodobeads  from Pierce Chemical Co., Rockford, 
IL; sodium-iodide-125 (12sI) from Amersham, Buckinghamshire, 
UK; high molecular weight standards, and coomassie  brilliant blue 
R-250 from Bio-Rad Laboratories, Richmond, CA. 
Animals.  Male  Lou rats used for the production ofmAb were 
obtained from the Harlan Olac Ltd., Blackthorn, Bicester, UK. 
Female and male BALB/c mice weighing 20-25 g and aged 3-6 
too, were originally obtained from The Jackson Laboratory, Bar 
Harbor, ME. BALB/c, ,u/nu mice were bred in the breeding fa- 
cility of the Central Laboratory of Animals of our University. All 
mice were kept in our animal laboratory by continuous brother- 
sister matings. 
Preparation of BB Suspensions  from Mouse Kidneys.  An enriched 
suspension of mouse renal BB membrane vesicles from proximal 
tubular epithelial  ceUs was prepared from BALB/c  kidneys  according 
to the method of  Malathi et al. (24), using a 2-ram Tris-HC1  buffer, 
pH 7.2, containing 50 mM mannitol, the protease  inhibitors EDTA 
(20 raM), PMSF (1 raM), benzamidine  (1 raM), Trasylol  (10 U/m1), 
and 0.02% NAN3. To obtain a BB preparation enriched in inte- 
gral membrane proteins that served as immunogen for the produc- 
tion of mAb, the crude BB fraction was solubilized  with the non- 
ionic detergent Triton-X-114 (2%) in 50 mM Tris-HC1 at 4~  for 
30 min and subjected to Triton X-114 phase separation at 37~ 
for 20 min followed by centrifugation at 300 g for 5 rain (25). 
In the immunoprecipitation procedure a BB fraction solubilized 
with 2% Triton X-100 in 50 mM Tris-HC1 at pH 7.2, without 
the protease inhibitors, was used. For the fluorimetric  enzyme assay 
BB membrane vesicles were solubilized with 1% Doc in 50 mM 
Tris-HC1 at pH 8.5, also without protease inhibitors for 30 min 
at 4~  and subsequently centrifuged at 100,000g for I h at 4~ 
The supernatant was then dialyzed  overnight at 40C against 0.1% 
Doc. Protein concentrations were determined by the method of 
Lowry et al. (26). 
Preparation ofmAb to APA.  A male Lou rat was immunized 
intraperitoneally with 1 ml of the detergent phase of the Triton 
X-114 extract of mouse BB and boosted by three intraperitoneal 
injections. 3 d after the last booster injection, spleen cells from 
the Lou rat were fused with SP 2/0 mouse myeloma cells by the 
procedure of K/Shler and Milstein (27), plated in 96-weU tissue cul- 
ture  plates with Hepes-buffered RPMI  1640, containing  10% 
decomplemented  FCS, gentamycin  (40 #g/ml), 1 mM t-glutamine, 
1 mM sodium pyruvate, 10% supernatant of a human umbilical 
vein cell culture, supplemented with HAT. Supernatants of wells 
containing growing hybridomas were tested for antibodies to an- 
tigens, present on both BB and glomerular epithelial cells, by in- 
direct immunofluorescence  (IF) on acetone-fixed  cryostat sections 
from normal BALB/c  kidneys. Selected  hybridomas producing an- 
tibodies of the desired spedficity were expanded after HAT selec- 
tion in conventional culture medium, and cloned several times by 
limiting dilution until all subclones  showed the same  reactivity  pat- 
tern in the indirect IF screening  procedure. 10 mAbs (listed  in Table 
1) were subsequently  produced in larger amounts by intraperitoneal 
inoculation of the cloned hybridomas in  BALB/c, ,u/nu  mice 
pretreated with pristane. Ascites samples were purified by ammo- 
nium sulfate  precipitation and tested for their nephritogenicity and 
their effect on the APA activity of mouse BB vesicles. The mAb 
coded as ASD-4 was selected for more extensive studies after fur- 
ther purification by chromatography on DEAE-sephacel. 
The IgG content of the antibody preparations was measured  by 
radial immunodiffusion (28). IgG subclasses were determined with 
an isotyping kit for rat mAb according to the instructions of the 
manufacturer (Serotec). The test system is based on rat cell agglu- 
tination using highly specific  antibodies directed to isotypes of rat 
Igs attached to sheep red calls (29). The purified ASD-4 was sub- 
jected to agarose isoelectric focusing to determine its isoelectric 
spectrotype. 
Imraunoprecipitation.  Mouse  renal BB membrane vesicles (23 
mg/ml) sohbilized by Triton >[-100 were radiolabeled with 12sI 
using Iodobeads as a coupling reagent (30). Free mI was removed 
by Sephadex G-25 chromatography. 100 #1 of protein A-agarose 
beads were  incubated  with  50  #1  of an  ammonium  sulfate 
precipitation-purified rabbit anti-rat Ig for 4 h at room tempera- 
ture. Supernatants  of three growing hybridomas  selected  by indirect 
IF and normal rat serum as a control were added to these beads 
and incubated overnight at 4~  under constant agitation. As addi- 
tional controls a goat anti-rat gp90 antiserum (kindly provided 
by Dr. E. de Heer, Department of Pathology, University Hospital 
Leiden, Leiden, The Netherlands) and normal goat serum were 
added to protein A-agarose beads loaded with rabbit anti-goat Ig. 
After several  washes  with immunoprecipitation  (IP) buffer (150 mM 
NaC1, 50 mM Tris, 5 mM EDTA, 0.1% [vol/vol] Triton X-100, 
0.02% [wt/vol] SDS, and 10 U/ml Trasylol), pH 7.4, 50 #1 of the 
radiolabeled mouse BB suspension was added to these beads and 
incubated for 2 h at room temperature. The beads were then washed 
over an AP-15 filter with the IP buffer several times. The beads 
were gently removed from the filter and heated in a SDS sample 
buffer (2.3% SDS, 200 mM dithiothreitol, 10% glycerol, 60 mM 
Tris-HC1 buffer, pH 6.8) for 5 min and spun down for 5 min in 
624  Monoclonal  Antibody to Mouse Aminopeptidase  A a microfuge. The immunoprecipitated proteins were analyzed on 
SDS-PAGE in 5-18% acrylamide gradients according to Laemmli 
(31). For autoradiography,  the gels were dried and exposed at - 70~ 
with preflashed x-ray film (Kodak XAR-5). 
Fhorimetric Enzyme Assay.  The specificity of ASD-4 for the 
hydrolase APA was determined by a solid phase immunodepletion 
procedure (16). The purified mAb was first coupled to cyanogen 
bromide-activated Sepharose 4B (S4B) according to the instruc- 
tions of the manufacturer.  Briefly,  5 mg of the selected  mAb in 
1 ml of 0.1 M carbonate buffer, pH 8.4, containing 0.5 M  NaC1 
was added per ml of S4B. Residual binding sites were saturated 
with 1 M ethanolamine. Then, 4 mg of a BB suspension solubi- 
lized by Doc and dissolved in 5 ml buffer was incubated for 18 h 
at 40C under constant stirring with 1 ml of S4B coupled to the 
mAb. A control BB suspension was prepared by performing a similar 
incubation of S4B beads to which no mAb had been coupled. The 
supernatant was removed and the beads were washed several times 
with buffer. Elution of the antigen bound to 1 ml of beads was 
performed with 5 ml of 50 mM diethylamine, suspended in 0.1% 
Doc,  at pH 12 for 5 min.  The eluted proteins were neutralized 
with 2 M Tris, pH 7.4. The enzymatic activities for APA, aminopep- 
tidase N  (APN),  and DPP IV were measured fluorimetrically in 
the control BB suspension, the immunodepleted suspension, and 
the eluate using Glu,AMC, AIa.AMC, and Gly.Pro.AMC as specific 
and sensitive substrates for APA, APN, and DPP IV, respectively 
(32).  For the determination of APA activity, the three fractions 
and the substrate were solubilized in 0.1 M Tris-HC1 buffer, con- 
taining 1.25 mM CaC12, pH 7.0. For APN activity, 0.1  M  Tris- 
HC1 buffer, pH 7.0, and for DPP IV activity 0.1 M phosphate buffer, 
pH 8.0, were used as solutions. 10/~1 of one of the three fractions 
was incubated with  100/~1 of one of the three substrates (2  x 
10 -4 M) for 20 min at 37~  The reaction was stopped by the ad- 
dition of 890/~1 of 0.2 M Tris-NaOH, pH 11. The enzyme activi- 
ties were determined  by the  fluorescence  of 7-amino-4-methyl- 
coumarin cleaved from the substrates (32). The fluorescence was 
measured at 370 nm (excitation) and 460 nm (emission) using a 
luminescence spectrometer (LS5; perkin-Elmer,  Norwalk, CT). The 
enzyme activities of the various fractions are expressed either as 
nanokatal/ml (1 nanokatal being the amount of enzyme that con- 
verts 1 nmol of substrate per second under the given assay condi- 
tions) or as percentages of the activities present in the control BB 
suspension. 
Effect of Various mAbs on APA Activity of  BB Vesicles.  The ability 
of the antibodies to block the APA activity on BB vesicles was 
tested in an inhibition enzyme assay. 20/zl of a BB preparation, 
containing 1/zg of protein, was incubated with 20/~1 of each of 
the mAbs, containing 5-10 #g IgG, for 10 min at room tempera- 
ture. Then, 40/zl of the substrate GIu.AMC (5  x  10 -4 M) was 
added to the suspension, which was incubated for another 30 min 
at 37~  The whole preparation was then dissolved in 0.1 M Tris- 
HC1, pH 7.0, with 1.25 mM CaCI2.  Hydrolysis of the substrate 
was stopped by adding 920/xl of 0.2 M Tris. NaOH, pH 11, and 
the enzyme activity was measured as described before. The enzyme 
activity of the starting BB suspension was expressed in nkatal/ml 
and the inhibition of the APA activity of the BB vesicles by the 
mAb is given as a percentage of residual activity. 
In Vivo Binding of the mAt~  Groups of five female BALB/c mice 
were injected intravenously via the tail vein with 0.5, 1, 2, 4, and 
8 mg of mAb ASD-4, respectively.  Albuminuria, as a sign of glo- 
merular protein leakage, was measured in 18-h urine samples col- 
lected I d before, and at days 1, 4, 8, and 16 after injection of the 
mAb. During their confinement in individual metabolic cages, the 
mice  received  only tap  water  ad  libitum  (33).  Pathological  al- 
buminuria was defined as a value greater than the normal mean 
plus 2 SD. Urinary albumin-concentrations were measured by radial 
immunodiffusion in  18-h urine samples,  using a goat antiserum 
against mouse albumin (28,  33).  The upper limit of the physio- 
logic albuminuria for females of this mouse strain is 86/xg of al- 
bumin excreted during an 18-h period. To determine the immuno- 
histological lesions, female BALB/c mice were injected intravenously 
with 4 mg ASD-4.  Groups of three mice were killed at days 1, 
4, 8,  and 14, and their kidneys were removed and processed for 
light microscopy (LM), IF, EM, and immuno-electron microscopy 
(IEM). 
The in vivo binding and the nephritogenic capacity of nine other 
mAbs, listed in Table 1, were studied by injecting 10 mg of mAb, 
purified by ammonium sulfate precipitation and dissolved  in 0.7 
ml of PBS, intravenously into groups of three female BALB/c mice. 
Albuminuria was measured at day 1, after which the kidneys were 
removed and processed for IF. 
Light  Microscopy, Immunofluorescence, and Electron Microscol~. 
Kidney fragments were fixed in Bouin's solution, dehydrated, and 
embedded in paraplast, and 2-/~m sections were stained with he- 
matoxylin and eosin, Periodic Acid Schiff, and Silver methenamine, 
as described earlier (11). For IF, kidney fragments were snap frozen 
in liquid nitrogen, and 2-/~m acetone-fixed cryostat sections were 
stained with FITC-labeled rabbit anti-rat IgG, absorbed with 40 
/zl/ml normal mouse serum, FITC-labded sheep anti-mouse IgG, 
absorbed with 40/~l/ml normal rat serum, and FITC-labeled goat 
anti-mouse C3 for 1 h. After rinsing in PBS, all sections  were em- 
bedded in Aquamount.  Binding of the mAb ASD-4 to normal 
mouse kidney was visualized with FITC-labeled rabbit anti-rat IgG 
in an indirect IF procedure.  The sections were examined in a fluores- 
cence microscope equipped with a Ploemopak epiillumination  (Leitz 
Letzlar GMBH, Wetzlar, Germany), and the staining intensity was 
recorded semiquantitatively on a scale from 0 to 4+  as described 
before (11). For EM,  small pieces  of cortex were fixed in 2.5% 
glutaraldehyde dissolved in 0.1 M  sodium cacodylate buffer, pH 
7.4,  for 4 h  at 4~  and washed in the same buffer. The tissue 
fragments were both fixed  in phosphate-buffered 2%  OsO4 for 
2 h, dehydrated,  and embedded in Epon 812.  Ultrathin  sections 
were cut in an ultratome (LKB Instruments, Bromma, Sweden) 
and stained with 4% uranyl acetate for 45 min and with lead citrate 
for 2 min at room temperature. The sections were examined in 
an electron microscope (300; Philips, Eindhoven, The Netherlands). 
Immuno-electron MicroscotT.  The localization of the antigen in 
a normal BALB/c kidney was examined by indirect IEM and the 
binding of the mAb to renal structures after intravenous injection 
into normal BALB/c mice by direct IEM using immunoperoxidase 
labeling on 20-#m frozen sections.  The left kidney of a BALB/c 
mouse was first perfused with PBS, pH 7.4, for 5 min and subse- 
quently with a mixture of periodate, lysine, and 2% paraformalde- 
hyde (PLP) for 10 rain (12). The kidney was removed and small 
cortical pieces were immersed for an additional 3 h. After rinsing 
several times in PBS, the fragments were cryoprotected by immer- 
sion in 2.3 M  sucrose,  pH 7.2, for 1 h, and then frozen in liquid 
nitrogen. The mAbs and all labded antisera were diluted in PBS 
containing 1% BSA. 20-#m thick sections were rinsed in PBS for 
1 h, then incubated with the mAb for 18 h at 4~  followed after 
several washes with PBS by incubation with a peroxidase-labeled 
rabbit anti-rat IgG, diluted  1:20,  for 1.5 h.  For the presence of 
mAb bound to the kidney after intravenous injection,  only the latter 
incubation step with the peroxidase-labeled  rabbit anti-rat IgG was 
performed. After three washes in PBS, the sections were incubated 
in diaminobenzidine (DAB) medium containing 0.6% Tris for 10 
min, followed by DAB with addition of 0.003% H202 for 7 min. 
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phosphate-buffered 2% OsO4 for 30 min at room temperature, de- 
hydrated, and embedded in Epon 812. Thin sections were prepared 
on an ultratome (LKB Instruments) and examined unstained in 
the electron microscope. 
StatisticalAnalysis.  For statistical analysis, Wilcoxon's rank sum 
test was used. p values <0.05 were regarded as significant. All values 
are expressed are means  •  SD. 
Results 
Characterization of mAbs.  Eight antibodies  that  showed 
an identical  localization in the kidney by indirect  IF, were 
directed  against  APA  (Table 1).  One mAb  (ASD-17)  was 
directed to a yet unidentified component of the glomerular 
and tubular basement membranes  (GBM;  TBM), while an- 
other  mAb  (ASD-43)  was  specific  for  DPP  IV  (data  not 
shown). The more extensively studied ASD-4 was of the IgG1 
subclass and showed three  distinct bands of isotypes  with 
pIs of 6.4, 6.7, and 6.9 by IEF (data not shown). The molec- 
ular mass  of the antigen recognized by ASD-4  was deter- 
mined by immunoprecipitation on radiolabeled mouse BB. 
As shown in Fig. 1, ASD-4 (lane 6) immunoprecipitated one 
band with an apparent molecular mass of 140 kD. Two other 
mAbs, coded ASD-2 and ASD-3, with an identical renal lo- 
calization in IF as ASD-4,  also bound to a 140-kD protein 
Table  1.  Characteristics of Eight  mAbs against Mouse 
Aminopeptidease  A 
Albuminuria at 
Code  mAb*  Subclass  day  1'  FEAS 
ASD-2  IgG1  18,079  _+  7,194  (3)  8 
ASD-3  IgG1  25,011  _+  11,249 (3)  8 
ASD-4  IgG1  18,033  +  5,564  (3)  10 
ASD-37  IgG2a  96  _+  10  (3)  18 
ASD-38  IgG2b  93  _+  31  (3)  116 
ASD-39  IgG2a  160  +_  121  (3)  22 
ASD-41  IgG2a  78  _+  35  (3)  93 
ASD-44  IgG2a  140  +  144  (3)  105 
ASD-17  IgG1  74  +  9  (3)  105 
ASD-43  IgG2b  107  +_  20  (3)  95 
PBS  -  104  _+  64  (5)  - 
Figure 1.  Autoradiogram of the immunoprecipitation  analysis  of radio- 
labeled mouse renal BB after SDS.PAGE  (5-18%). Lane I, whole BB prep- 
aration; lane 2, polyclonal anti-mouse  DPP IV; hne 3, normal goat serum; 
lanes 4 (ASD-2) and 5 (ASD-3), two different rat mAb directed to APA; 
lane 6, ASD-4, a rat mAb against APA described in the study. The numbers 
in the figure indicate the molecular mass of the markers. 
" All mAbs were purified by ammonium sulfate precipitation.  ASD-17 
is directed  to  an as yet unidentified component of GBM/TBM,  and 
ASD-43 is directed  to DPP IV. 
10 mg of mAb dissolved in 0.7 ml of PBS or 0.7 ml PBS alone was 
injected intravenously  into BALB/c mice. Numbers of mice appear be- 
tween parentheses.  Data are micrograms  of albumin per 18 h. 
s Residual APA activity of BB vesicles  after preincubation with the mAb 
in the fluorimetric enzyme assay (FEA). Original activity in the prepara- 
tion was 9.4 nkatal/ml. 
Figure 2.  Enzymatic activities of APA, APN, and DPP IV measured 
in three fractions using a fluorimetric  enzyme assay. A Doc-solubilized 
BB fraction (T; filled Mrs), a BB fraction immunodepleted with ASD-4 
coupled to Sepharose-4B  beads (A; hatched  ban), and a fraction duted from 
the beads (E; open bar). Enzymatic activities are given as percentages of 
the activities in the starting material (100%). The original activities were 
5.6, 34.7, and 12.3 nkatal/ml for APA, APN, and DPP IV, respectively. 
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of a Normal BALB/c Mouse 
Renal structure  Staining intensity 
Glomerulus 
Visceral epithelium 
Endothelium 
Juxtaglomerular cells 
Proximal tubule 
Brush border 
-6++ 
m 
+ 
S1  +++ 
$2  +++ 
$3  -+ 
Peritubular capillaries 
Cortex  + 
Medulla  + + 
Arteries 
Muscle cell membranes  + 
Staining intensity was detected with ASD-4 using the indirect  immu- 
nofluorescence technique. 
(lanes 4 and 5). A low molecular mass band is also seen in 
lane 6, probably as a degradation product. A polyclonal an- 
tiserum against mouse DPP IV precipitated two bands, one 
with a molecular mass of 108 kD, and the other with a mo- 
lecular mass of 80 kD (lane 2).  Normal rat or goat serum 
(lane 3) did not precipitate  any protein from the BB suspension. 
Specificity of the raAl~  The specificity of ASD-4 was de- 
termined by an immunoadsorption procedure using Sepharose- 
4B beads coated with ASD-4 to deplete the spedfic antigen 
from the BB suspension. As shown in Fig. 2, enzymatic ac- 
tivities could be detected in the Doc-solubilized BB prepara- 
tion for APA, APN, and DPP IV using specific substrates 
in the fluorimetric enzyme assay. APA activity was sdectively 
depleted from the starting material by the immunoadsorbent, 
which did not influence the enzymatic activities for APN 
and DPP IV. A basic elution step could recover "~38% of 
the enzymatic activity for APA, but not for DPP IV and 
APN. The incomplete recovery of the enzymatic activity for 
APA by the elution is most likely caused by the partial inac- 
tivation of  APA due to the high pH used for the elution pro- 
cedure. These resuhs,  which were confirmed in two addi- 
tional experiments, strongly suggest that the antigen to which 
ASD-4 bound has an enzymatic activity of APA. 
Localization of  APA in Normal Mouse Kidneys.  By indirect 
IF, APA could be detected in several  defined areas of  the mouse 
kidney (Table 2). ASD-4 strongly stained the visceral epithe- 
lium of the glomerulus and the BB of the convoluted prox- 
imal tubules  (Fig. 3 A). In addition,  it stained to a lesser 
extent the juxtaglomerular ceUs (Fig. 3 A), the BB of the 
straight parts  of the convoluted  proximal  tubules,  the en- 
dothelial cells of the peritubular capillaries, especially those 
located in the medulla (Fig. 3 B), and the cell membranes 
of the smooth musde cells of  arteries. Minimal staining could 
also be seen  in the basal parts of some cells of the convoluted 
proximal tubules. The endothdial ceUs of arteries and veins 
were negative. 
By indirect IEM, the antigen was homogeneously  present 
on the cell membranes of the glomerular visceral epithelia. 
Figure  3.  Indirect immune  fluorescence of a normal BALB/c kidney incubated with ASD-4. (A) Strong homogeneous fluorescence along the capillary 
wall of the glomerulus  and the BB of the proximal  tubules  is present.  Fine granular staining of the juxtaglomerular cells can also be seen (arrow) 
(x800). (B) Strong binding to the BB of the convoluted part and faint binding to the straight  part (arrow) of the proximal tubules can be observed. 
Endothelia  of the peritubular capillaries are also positive (arrowhead) (x 530). 
627  Assmann et al. Figure  4.  Indirect  immuno-electron  microscopy  of  a  normal BALB/c kidney  incubated  with  ASD-4. A-C Immunopcroxidase labeling.  (A)  A higher 
magnification of a capillary loop with the homogeneous staining of the cell membranes of the visceral epithelial cell and the staining of some multive- 
sicular bodies and the endoph~mlc reticulum (arrows) (x20,600). Cap, capillary lumen; Ep, epithelial cell; US, urinary space. (B) Homogeneous staining 
of the BB of convoluted prc~mal tubules and some vesicles. (x10,175).  (C) Discrete loci of staining of the basolateral membranes of the convoluted 
proximal  tubule (arrow), and some staining  of the endothelium  of a peritubvlar  capillary (amavhead) (x44,000). 
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Intravenous Injection of ASD-4 
Dose  Albuminuria* 
rag 
-  34  _+  23  (30)* 
0.5  37  _+  20  (5) 
1  66 +  42  (5) 
2  1,133 +  502 s  (5) 
4  4,555  _+  1,920  s  (5) 
8  12,035  +  7,543s  (5) 
* Data show micrograms albumin per 18 h. 
* Numbers of mice are in parentheses. 
$ Significant different  from untreated mice, (p < 0.02). 
but not on endothdial or mesangial cells (Fig. 4 A). In addi- 
tion, it was strongly and diffusely present on the BB (Fig. 
4 B) and focally on the basal  lateral cell membranes of the 
convoluted proximal tubules (Fig. 4 C). The presence of the 
antigen on the endothelial cells of the peritubular capillaries 
(Fig. 4 C), muscle cells of arteries, and to a lesser extent on 
the BB of the straight parts of the proximal tubules, was 
also confirmed by IEM. Intracellularly, the antigen could be 
demonstrated in small or multivesicular bodies, in the en- 
doplasmic reticulum of the glomerular epithelial cells (Fig. 
4 A), and on the cell membranes of small vesicles just below 
or pinching off the base of BB of the convoluted proximal 
tubules (Fig. 4 B). The distal tubules, collecting ducts, loops 
of Henle, and all basement membranes were negative. 
Induction of  Albuminuria in Normal BALB/c Mice.  When 
BALB/c mice were injected intravenously with increasing 
(0.5-8 mg) amounts of ASD-4, an albuminuria could be in- 
duced at day I with doses >1 mg of mAb, which was mas- 
sive with a dose of 8 mg (Table 3). The albuminuria remained 
lOS I  --V-Jq  ~"'~  -*-:q  "~:q  1 
￿9  2  4  6  8  tO  12  14  16 
Figure 5.  Aibnmlnm'ia  in BALB/c  mice after injection  of 1, 2, 4. and 
8 mg of  ASD-4. Albnminuria  is given  as total amount  of  albnmin in 18-h 
urine samples (mean). The dashed line represents the upper limit of the 
physiologic albuminuria. 
high and had not returned to normal values 16 d after the 
injection of the mAb (Fig. 5). Mice injected with doses >8 
mg became severely ill at the end of their contingent in 
the metabolic cages at day I and most did not survive. Injec- 
tion of 8 mg of a rat mAb with the same isotype as ASD-4 
and directed to an as yet unidentified antigen present on glo- 
merular epithelia and endothelia resulted in strong glomer- 
ular binding but not in a pathologic albuminuria (data not 
shown). 
In Vivo Binding of  AaD-4 to Renal Structu,rx  Injection of 
4 mg of  ASD-4 into normal mice led to an immediate binding 
to the glomerular capillary wall in a pattern that was homo- 
geneous as seen by direct IF at 1 h (Table 4, Fig. 6 A). This 
prominent staining pattern changed gradually into a more 
granular, membranous pattern after 1 d. At day 14, the rat 
mAb was present in fine granules along the capillary wall 
Table 4.  Iramunofluorescence  Findings in BALB/c Mice after Injection of 4 mg ASD-4 
Glomerulus 
Proximal  tubule 
BB  BL 
Time  Ra.IgG  M.IgG  M.C3  (Ra.lgG)  (Ra.IgG) 
lh  ++h  -  -  +  - 
4h  +++h  -  -  ++  - 
lh  +++g  -  -  ++  + 
3d  ++g  -  -  -  +++ 
8d  +++g  -+  -  -  +++ 
14d  +++g  ++  +  -  - 
BB, brush border; BL, basolateral membranes; Ra, rat; M, mouse; h; homogeneous  staining pattern, g; granular staining pattern. 
* Only a few granules in the capillary wall of some glomeruli. 
629  Assmann  et al. Figure 6.  Direct  immunofluorescence  of kidneys of mice after intravenous administration of ASD-4. (A) Homogeneous  binding to the glomerular 
capillary wall at 1 h (xS00). (B) Fine granular binding in a membranous pattern at day 14 (x 800). (C) Binding to the BB of the convoluted  proximal 
tubules at day 1 (G, glomerulus) (x320). (D) Finely striped or more prominent binding to the basal parts of the convoluted  proximal tubules at day 
8. Binding to the BB has disappeared at this time (x640). 
now also complexed with mouse IgG and in a few glomeruli 
with traces of mouse C3 (Fig.  6 B). The glomerular binding 
was accompanied by a transient  binding  to  the BB of the 
convoluted proximal tubules during the first days after injec- 
tion,  followed by a strong binding  to the basolateral parts 
of the convoluted proximal tubulus (Fig. 6, C  and/9).  The 
binding to the BB was already present at 1 h after injection 
of the antibody (Table 4). During the first 8 d after injection, 
the mAb was also found on endothelial cells of the peritubular 
capillaries.  2 wk after injection, the mAb could only be ob- 
served in the glomerular capillary wall and to a lesser extent 
on  the muscle cells  of small  arteries. 
The distribution of the injected mAb could be examined 
more precisely by direct IEM using the immunoperoxidase 
labeling technique.  1 h  after injection,  ASD-4 was present 
particularly on the basal cell membranes and slit pores of the 
foot processes of the glomerular visceral epithelial cells, and 
sometimes also on the urinary  side of some foot processes 
(Fig.  7 A).  After  1 d, binding  of ASD-4 to the cell mem- 
branes of the epithelial cells became gradually more variable 
and restricted to the slit pores, while in addition fine granular 
deposits appeared under the foot processes and in the slit pores. 
At day 14, the mAb could only be detected on the cell mem- 
branes of the epithelial cells near the slit pores or as deposits 
630  Monoclonal  Antibody to Mouse Aminopeptidase A Figure 8.  Ultrastructural findings 14 d after injection of ASD-4. A. 
Complete effacement  of the foot processes  of the visceral epithelial ceUs 
is present (x18,400). Ep, epithelial cell. 
Figure 7.  Direct  immuno-electron microscopy  of kidneys of mice after 
intravenous injection of ASD-4. (A) Binding is seen in the slit pores and 
on the cell membranes of the glomerular visceral epithelial cells at 1 h 
(x16,530). (B) At day 14, ASD-4 is present on the cell membranes of 
the foot processes  along the slit pores (arrow)  and in small deposits  below 
the epithelial ceils (x19,600). 
in  the  slit  pores  and below the  foot processes (Fig.  7 B). 
Binding of ASD-4 was always restricted to the epithelial side 
of the GBM. The GBM itself, mesangium,  and endothelial 
calls did not show binding during the time of observation. 
ASD-4 could also be detected on the BB and subsequently 
in the basolateral parts of the convoluted proximal tubules, 
as well as on the endothelia of the peritubular capillaries  as 
already described for IF. 
Morphologic Changes after Injection of  ASD-4.  By LM, no 
glomerular  lesions could be observed during the first 2 wk 
after injection  of the mAb,  notably no influx of polymor- 
phonuclear leukocytes (PMN), platdets, or mononudear cells 
could be seen. However, the ceils of the convoluted and straight 
parts of the proximal tubulus became gradually more findy 
vacuolated.  At the ultrastructural  level at day 1, partial  fu- 
sion of the foot processes of the visceral epithelia could be 
observed, which was almost complete 14 d  after the injec- 
tion of the mAb (Fig. 8). No abnormalities of the endothelia 
or mesangium could be seen. Only at day 14 were a few widely 
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scattered electron-dense immune deposits visible in the slit 
pores of the visceral epithelia. 
Nephritogenic Properties  and Effects on APA Activity of Other 
raAbs to APA.  Injection of two other mAbs to APA (ASD-2 
and ASD-3)  caused a massive albuminuria  at  day 1 (Table 
1). Like ASD-4,  they could reduce the APA activity on BB 
vesicles by ,,090%. Five other mAbs to APA were unable to 
induce enhanced glomerular permeability at day 1 with al- 
bumin excretions remaining not different from the values ob- 
tained with 0.7 ml of PBS alone or with  the two control 
mAbs.  Two of these mAbs, ASD-37 and ASD-39,  also in- 
hibited the enzymatic  activity of the BB vesicles  consider- 
ably, while the  three remaining  mAbs,  ASD-38,  ASD-41, 
and ASD-44, had no inhibitory effect on APA activity (Table 
1). All mAbs that had similar,  high binding titers in the in- 
direct IF on normal mouse kidneys showed comparable glo- 
merular  binding  1 d  after injection  into  the mice. 
The control mAbs ASD-17 and ASD-43 did not induce 
albuminuria  at day 1,  despite a strong binding  to the glo- 
merular  capillary wall as seen by direct IF.  They were also 
not  able to influence  the APA activity on BB vesicles. 
Discussion 
Proteinuria  is an important  hallmark  of glomerular  dis- 
ease, and several mechanisms that mediate enhanced glomer- 
ular permeability have now been delineated in a variety of 
experimental models (reviewed in references 1 and 3). In this 
report  we describe a rat  mAb  that  showed unique  protei- 
nuric properties after a single intravenous  injection into normal 
mice.  The  albuminuria  was dose dependent  and lasted for 
at least 16 d. Its induction did not seem to be related to any 
of the known systemic mediators of glomerular injury, such 
as complement,  coagulation  factors,  monocytes,  PMN,  or 
platelets.  A  rapid,  homogeneous binding  to the cell mem- 
branes of the glomerular visceral epithelial  ceUs was observed, 
which very soon became finely granular with a preferred lo- calization in the slit pores of the epithelial cell foot processes. 
These subepithelial deposits were accompanied by an efface- 
ment of the foot processes of the glomerular visceral epithe- 
lial ceUs. There was no cell detachment as seen in some models 
of experimental glomerulonephritis. 
Besides the immediate binding to the glomerular capillary 
wall, a transient binding of ASD-4 to the BB of the con- 
voluted proximal tubules, obviously due to the massive leakage 
through the glomerular filter, was seen during the first 2 d 
after injection of the mAb. Staining of the BB was seen as 
early as 1 h after injection, suggesting that the protein leakage 
started almost immediately. This was followed by a binding 
to the basolateral membranes of these cells, which had disap- 
peared at day 14. The time sequence of binding of ASD-4 
to the different parts of the convoluted proximal epithdial 
cells suggests an active transport of the mAb through the 
cytoplasm to the basolateral membranes after binding to the 
BB. An alternative explanation might be that ASD-4 can bind 
directly to the basolateral membranes via the peritubular capil- 
laries after an upregulation of APA at these membranes, which 
show minute amounts of enzyme in normal, physiological 
circumstances as shown by indirect IF and IEM. 
The evidence that ASD-4 is directed against the hydrolase 
APA (angiotensinase A) was based on several data. (a) ASD-4 
bound in the immunoprecipitation procedure to an antigen 
with a molecular mass identical to that reported for APA 
isolated from murine pre-B cells, i.e., 140 kD (34). (b) ASD-4 
could deplete APA activity from a mouse BB preparation 
without affecting the activities for APN and DPP IV. (c) A 
mild elution procedure with a basic buffer could specifically 
recover nearly 40% of the activity for APA from Sepharose- 
4B beads used in the immunoadsorption procedure. (d) The 
presence of APA in the mouse kidney corresponds to the lo- 
calization of APA as previously assessed by histochemical 
studies (35).  From these histochemical studies it is already 
known that the two hydrolases,  DPP IV and APA, have al- 
most identical localizations in the mouse and rat kidney (7, 
35-41).  Both proteins are prominently present on the cell 
membranes of the glomerular visceral epithelial cells, on BB 
of the proximal tubular cells, and on endothelial ceils. There 
are, however, several differences: APA is absent from the glo- 
merular endothelial ceils and only moderately present on the 
straight parts of the proximal tubules in contrast to DPP IV, 
which is located on both structures. In addition, APA is also 
present in juxtaglomerular cells and on cell membranes of 
smooth muscle cells of arteries. In all these respects ASD-4 
localized in our study in a pattern similar to that of APA. 
Besides differences in localization, the two hydrolases,  DPP 
IV and APA, show different molecular masses and different 
reactions after binding with their respective mAb. In prelim- 
inary studies with several rat mAbs against mouse DPP IV 
produced in our laboratory, we found an immediate homo- 
geneous binding to the glomerular capillary wall that showed 
no redistribution during 8 d after intravenous injection. Fur- 
thermore, we could not induce albuminuria, even when doses 
up to 15 nag of mAb were injected. Polyclonal antibodies 
against mouse DPP IV caused a minor, transient albuminuria, 
which was only a fraction of the albuminuria induced by 
ASD-4 (11). 
Recently, the eDNA sequence of APA purified from an 
Abdson murine leukemia virus-transformed routine pre-B 
cell line was elucidated (42).  APA, formerly known as the 
murine B lymphocyte antigen BP-1/6C3 present on normal 
and transformed pre-B and immature B lymphocytes, proved 
to be a homodimeric, phosphorylated cell surface glycopro- 
tein with subunits of 140 kD present on a variety of hemato- 
poietic and epithdial cells (39).  The eDNA sequence deter- 
mined a type II integral membrane protein of 945 amino acids 
with an intracytoplasmic NH2 terminus of only 17 amino 
acids and a typical zinc-binding motif in the extracellular do- 
main. Despite this, APA is a zinc-independent enzyme that 
needs Ca  2+ at its active site as a necessary requirement for 
its ~  activity. Although most APA are cell membrane bound, 
a soluble form can also be detected in the serum, generated 
most likely by proteolytic cleavage from the membrane form. 
The functions of APA present on cell membranes of many 
cell types, together with several ectoenzymes, are varied and 
are related to digestion and absorption of peptides in the renal 
tubules or to a regulatory role in several regulatory systems 
on  cells.  APA  has  a  weU-known function  in  the  renin- 
angiotensin system by cleaving the NH2-terminal amino acid 
aspartate from the angiotensin II and to a lesser extent also 
from angiotensin I (34, 38,  39).  It is one of the so-called 
angiotensinases involved in the rapid inactivation of the an- 
giotensins. The octapeptide angiotensin II is the most active 
pressor substance of the renin-angiotensin system, which con- 
trols systemically or locally many functions in nearly every 
organ (43-46). With respect to the kidney, it is particularly 
involved in the control of renal and glomerular blood flow, 
the glomerular filtration rate, and the absorption of sodium 
ions by tubular cells (47). In addition to these hemodynamic 
and homeostatic functions, angiotensin II has also mitogenic 
properties and may thus have a function as a growth factor 
(48).  The localization  of APA in the kidney corresponds 
roughly to the localization of the receptors for angiotensin 
II and suggests a regulatory role of APA in the different func- 
tions of angiotensin II. Receptors for angiotensin II have been 
demonstrated in the glomeruli, particularly on mesangial cells, 
on smooth muscle cells of vessels, on vasa recta bundles in 
the renal medulla, and on proximal tubular cells (49-51). In 
the glomerulus, binding of angiotensin II to its receptor on 
mesangial cells induces contraction of these cells influencing 
the glomerular capillary surface area available for filtration 
and  consequently  the  glomerular  capillary  uhrafiltration 
coefficient (Kf) (51). At this moment, it is thought that APA 
on glomerular epithelial cells may bind and rapidly inacti- 
vate angiotensin II delivered to the glomerulus and then filtered 
via the capillary wall (52,  53). 
It is not clear how the binding of the mAb to APA on 
the  glomerular visceral  epithelial  cells  can  induce  an  al- 
buminuria in mice. At least two possible mechanisms may 
be operating in this model during the first 16 d after injec- 
tion of the mAb that act either alone or synergistically. The 
first mechanism may be hemodynamically  determined by the 
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giotensin II to APA and its subsequent inactivation, leading 
to a prolonged and enhanced effect of this pressure peptide 
on the glomerular circulation and the traf~c of proteins across 
the glomerular capillary wall. In several experimental condi- 
tions, it has been shown that exogenous as well as endoge- 
nous angiotensin II can increase the excretion of proteins in 
rats by hemodynamic factors (54, 55). The proteinuria de- 
scribed in these studies, however, is of short duration, most 
probably due to the rapid inactivation of angiotensin II. Al- 
though the results of the three nephritogenic mAbs that can 
inhibit the APA activity on BB vesicles are in line with this 
mechanism, the data obtained with  two of the five non- 
nephritogenic mAbs that also could reduce enzymatic activity 
do not support  the hypothesis that blocking of the active 
site on APA alone is responsible for the induction of the al- 
buminuria. 
Therefore, a second mechanism, probably related to a di- 
rect disturbance of the glomerular filter by the deposited 
ASD-4, might be more important in this model. There are 
several reports in which heterologous polyclonal antibodies, 
directed against antigens on glomerular visceral epithelial cells 
and mostly of noncomplementing-fixing subclass,  are able 
to induce proteinuria without the activation of complement, 
coagulation  factors,  or  the  influx  of inflammatory cells 
(reviewed in reference 3).  The mechanism by which these 
antibodies cause proteinuria is not clear, but it has been pro- 
posed that the binding of mAb to cell membrane-associated 
proteins causes the release from the epithelial cell, of cytokines, 
or other as yet undefined compounds that induce physico- 
chemical alterations in the GBM leading to enhanced perme- 
ability (3). 
Each of these supposed mechanisms could be responsible 
for the acute occurrence of albuminuria after the injection 
of ASD-4. It is likely that autologous antibodies, which be- 
came bound to the primary deposits of heterologous rat an- 
tibodies at later stages,  and which apparently did not lead 
to activation and deposition of complement, contributed to 
the persistence of the proteinuria. 
In contrast to the studies with polyclonal antibodies, most 
attempts to induce a proteinuria with single injections of mAbs 
directed against glomerular visceral epithelial ceUs have failed. 
In recent years,  two mAbs have been described that could 
induce a complement- and cell-independent proteinuria in 
rats (17,  21). The first mAb against a 115/107-kD  protein 
on glomerular visceral epithelial ceUs evoked a transient pro- 
teinuria lasting  6-8  d,  but  only when given in  excessive 
amounts (66 mg of mAb) to rats pretreated with CFA (17). 
The second mAb against a 56-kD protein present on the slit 
diaphragms of the glomerular visceral epithelial cells caused 
a proteinuria that lasted for ~2 wk (21). 
In addition to its ability to induce a reproducible and per- 
sistent proteinuria in mice, ASD-4 has the advantage of being 
directed against a molecule of which the localization and the 
functions are well known. It is important to note that not 
every antibody against APA will cause albuminuria. Appar- 
ently the antibody must be directed against specific epitopes 
on the APA molecule, since we found that some of the other 
antibodies against APA, prepared in a similar way by us, did 
not induce proteinuria, although their in vitro and in vivo 
binding pattern was identical to that of ASD-4. 
The antibody described here provides an opportunity to 
study the pathogenic mechanisms of proteinuria in a model 
in which the well-known secondary mediator systems do not 
appear to play a role. Studies in which we try to elucidate 
the role of angiotensin II inactivation by ASD-4 on the glo- 
merular circulation and the ensuing albuminuria are now under 
way in our laboratory. 
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